Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 20

Sort by

Sort Order Select

Journal Articles

MRD4 Eradication at 6 Months and Early Clearance of MRD with Combination of Ibrutinib Plus Venetoclax Results in Sustained Clinical and MRD Responses: Exploratory Analysis of the Blood Cancer UK TAP Clarity Study

Blood (2022) 140 (Supplement 1): 222–223.

https://doi.org/10.1182/blood-2022-166700

Published: 2022

Journal Articles

Ibrutinib and Obinutuzumab in CLL: MRD Responses Sustained for Several Years with Deepest MRD Depletion in Patients with >1 Year Prior Ibrutinib Exposure

Andy C. Rawstron, PhD, Peter Hillmen, MBChB, FRCP, FRCPath, PhD, Shanna Maycock, BSc, MSc, Nichola Webster, Kristian Brock, PhD, Rebecca H. Boucher, BSc, MSc, PhD, Francesca Yates, PhD, Rebecca Jarvis, BSc, Surita Dalal, PhD, Ruth M. de Tute, PhD FRCPath, Paul Moss, MBBS, PhD FRCP, Donald Macdonald, MBChB, MD FRCP, PhD FCRPath, Piers Patten, MD PhD, Christopher Fegan, Andrew Pettitt, MA, MB BChir, PhD MRCP, MRCPath, Christopher P. Fox, MD PhD, Adrian Bloor, PhD FRCP, FRCPath, Oonagh Sheehy, MB BCh BAO, MRCP, FRCPath, Peter Hillmen, MBChB, PhD

Blood (2020) 136 (Supplement 1): 27–28.

https://doi.org/10.1182/blood-2020-136990

Published: 2020

Journal Articles

Continued Long Term Responses to Ibrutinib + Venetoclax Treatment for Relapsed/Refractory CLL in the Blood Cancer UK TAP Clarity Trial

Blood (2020) 136 (Supplement 1): 17–18.

https://doi.org/10.1182/blood-2020-136960

Published: 2020

Journal Articles

Ibrutinib and Obinutuzumab in CLL: Improved MRD Response Rates with Substantially Enhanced MRD Depletion for Patients with >1 Year Prior Ibrutinib Exposure

Andy Rawstron, PhD, Talha Munir, Kristian Brock, MSc, BSc, Nichola Webster, Samuel Munoz Vicente, MSc, Francesca Yates, PhD, Sophie Cramp, MSc, BSc, Rebecca Bishop, BSc, Surita Dalal, PhD, Ruth M De Tute, BSc,MSc, Oonagh Sheehy, Andrew Pettitt, FRCPath, PhD, Christopher P. Fox, MD PhD, Stephen Devereux, PhD, Christopher Fegan, MD, Donald MacDonald, Adrian Bloor, MA MB BChir PhDFCRP FRCPath, Peter Hillmen, MB ChB, PhD FRCP, FRCPath

Blood (2018) 132 (Supplement 1): 181.

https://doi.org/10.1182/blood-2018-181

Published: 2018

Journal Articles

Ibrutinib Plus Venetoclax in Relapsed/Refractory CLL: Results of the Bloodwise TAP Clarity Study

Peter Hillmen, MB ChB, PhD FRCP, FRCPath, Andy Rawstron, BSc, PhD, Kristian Brock, MSc, BSc, Samuel Munoz Vicente, MSc, Francesca Yates, PhD, Rebecca Bishop, BSc, Donald Macdonald, Christopher Fegan, MD, Alison McCaig, PhD, Anna Schuh, MD PhD, Andrew Pettitt, FRCPath, PhD, John G. Gribben, Piers E.M. Patten, BSc, MRCP, MRCPath, PhD, Stephen Devereux, PhD, Adrian Bloor, MA MB BChir PhDFCRP FRCPath, Christopher P. Fox, MD PhD, Francesco Forconi, MD DM, PhD FRCPath, Talha Munir

Blood (2018) 132 (Supplement 1): 182.

https://doi.org/10.1182/blood-2018-182

Published: 2018

Journal Articles

Initial Results of Ibrutinib Plus Venetoclax in Relapsed, Refractory CLL (Bloodwise TAP CLARITY Study): High Rates of Overall Response, Complete Remission and MRD Eradication after 6 Months of Combination Therapy

Peter Hillmen, MBChB, PhD, Talha Munir, Andy Rawstron, PhD, Kristian Brock, MSc, BSc, Samuel Munoz Vicente, MSc, Francesca Yates, PhD, Rebecca Bishop, BSc, Christopher Fegan, MD, Donald Macdonald, Alison McCaig, PhD, Anna Schuh, MD PhD, Andrew Pettitt, FRCPath, PhD, John G. Gribben, MDDSc FMedSci, Stephen Devereux, FRCP, FRCPath, PhD, Adrian Bloor, Christopher P Fox, MBChB PhD, Francesco Forconi, MD DM, PhD FRCPath

Blood (2017) 130 (Supplement 1): 428.

https://doi.org/10.1182/blood.V130.Suppl_1.428.428

Published: 2017

Journal Articles

The Bloodwise TAP Calibre Feasibility Study to Assess the Mechanism of Action of Idelalisib in B-Cell Receptor Pathway (BCR) Inhibition in Chronic Lymphocytic Leukaemia (CLL)

Talha Munir, Peter Hillmen, MBChB, PhD, Andy Rawstron, PhD, Kristian Brock, MSc, BSc, Samuel Munoz-Vicente, Francesca Yates, PhD, Surita Dalal, PhD, Ruth M de Tute, PhD FRCPath, Chris P Fox, Donald Macdonald, Christopher Fegan, MD, Adrian Bloor, Anna Schuh, MD PhD, Gina Doody

Blood (2017) 130 (Supplement 1): 3014.

https://doi.org/10.1182/blood.V130.Suppl_1.3014.3014

Published: 2017

Journal Articles

Preconditioning Neutropenia Is a Key Prognostic Factor in Allogeneic Hematopoietic Cell Transplantation for High Risk Acute Myeloid Leukemia

Philippa J Rohman, Richard M Szydlo, Emily Hobbs, Renuka Palanicawandar, Belen Sevillano, Silvia Monsalvo, Andrew Innes, Edward J Kanfer, Dragana Milojkovic, Ian H Gabriel, Christian Jakob, Donald Macdonald, Aristeidis Chaidos, Anastasios Karadimitris, Jane F Apperley, Eduardo Olavarria, Jiří Pavlů

Blood (2016) 128 (22): 3411.

https://doi.org/10.1182/blood.V128.22.3411.3411

Published: 2016

Journal Articles

Updated Analysis of Overall Survival in Randomized Phase III Study of Idelalisib in Combination with Bendamustine and Rituximab in Patients with Relapsed/Refractory CLL

Andrew D. Zelenetz, Jennifer R. Brown, Julio Delgado, Herbert Eradat, Paolo Ghia, Abraham Jacob, Wojciech Jurczak, Javier Loscertales, Donald MacDonald, Franck Morschhauser, Javier De la Serna, Mazyar Shadman, Christopher Pocock, Adeboye Henry Adewoye, Yeonhee Kim, David Simpson, Stephan Stilgenbauer

Blood (2016) 128 (22): 231.

https://doi.org/10.1182/blood.V128.22.231.231

Published: 2016

Journal Articles

The Intensive Care Trial for Critically Ill Onco-Haematologic Patients: The Need for Response Criteria at 5 Days of Full Treatment to Separate Good Risk Patients and Avoid Futile Intensive Care Interventions

Blood (2016) 128 (22): 5987.

https://doi.org/10.1182/blood.V128.22.5987.5987

Published: 2016

Journal Articles

Addition of Obinutuzumab to Ibrutinib Enhances Depletion of CLL Cells in the Peripheral Blood and Bone Marrow after 1 Month of Combination Therapy: Initial Results from the Bloodwise TAP Iciclle Extension Study

Andy C Rawstron, BSc, PhD, Talha Munir, Samuel Muñoz-Vicente, Kristian Brock, MSc, BSc, Francesca J Yates, PhD MSci, Rebecca Bishop, BSc, Surita Dalal, Ruth Mary de Tute, PhD FRCPath, Adrian Bloor, Oonagh M Sheehy, MB BSc FRCP FRCPAth, Andrew R. Pettitt, Christopher P Fox, MBChB, MRCP, FRCPath, Christopher Fegan, Stephen Devereux, PhD FRCP, FRCPath, Donald Macdonald, Peter Hillmen

Blood (2016) 128 (22): 2049.

https://doi.org/10.1182/blood.V128.22.2049.2049

Published: 2016

Journal Articles

Impact of Nutrition on Non-Relapse Mortality and Acute Graft Versus Host Disease during Allogeneic Hematopoietic Cell Transplantation for Hematologic Malignancies

Julie Beckerson, Richard M Szydlo, Mary Hickson, Catriona E Mactier, Andrew Innes, Ian H Gabriel, Renuka Palanicawandar, Edward J Kanfer, Donald Macdonald, Dragana Milojkovic, Amin Rahemtulla, Aristeidis Chaidos, Anastasios Karadimitris, Eduardo Olavarria, Jane F. Apperley, MD, Jiří Pavlů

Blood (2016) 128 (22): 2226.

https://doi.org/10.1182/blood.V128.22.2226.2226

Published: 2016

Journal Articles

Third Autologous Stem Cell Transplantation for Relapsed Multiple Myeloma

Catherine Garnett, Chrissy Giles, Maialen Lasa, Osman Ahmed, Marco Bua, Holger W. Auner, Donald MacDonald, Sasha Marks, David Marin, Dragana Milojkovic, Jiri Pavlu, Saad Abdalla, Edward J Kanfer, Jane Apperley, Amin Rahemtulla

Blood (2012) 120 (21): 4548.

https://doi.org/10.1182/blood.V120.21.4548.4548

Published: 2012

Journal Articles

Tandem Autologous Stem Cell Transplantation in Chemorefractory Multiple Myeloma

Catherine Garnett, Chrissy Giles, Osman Ahmed, Maialen Lasa, Holger W. Auner, Donald MacDonald, Sasha Marks, David Marin, Dragana Milojkovic, Jiri Pavlu, Marco Bua, Saad Abdalla, Edward J Kanfer, Jane Apperley, Amin Rahemtulla

Blood (2012) 120 (21): 4554.

https://doi.org/10.1182/blood.V120.21.4554.4554

Published: 2012

Journal Articles

The Majority of Patients Receiving Donor Lymphocyte Infusions for Relapsed Chronic Myeloid Leukemia Remain PCR Positive Despite Maintaining Long-Term Remission,

Andrew J Innes, MBChB, James Lurkins, Richard M Szydlo, Andrea Guerra, Dragana Milojkovic, MD, Jiri Pavlu, Edward J Kanfer, David Marin, Donald MacDonald, Amin Rahemtulla, Sandra Loaiza, Stephanie Kirschke, Katayoun Rezvani, MD, PhD, John Goldman, Jane F Apperley, MBChB, MD, FRCP, FRCPath, Francesco Dazzi

Blood (2011) 118 (21): 4103.

https://doi.org/10.1182/blood.V118.21.4103.4103

Published: 2011

Journal Articles

Interaction between KIR3DS1 and HLA-Bw4 predicts for progression-free survival after autologous stem cell transplantation in patients with multiple myeloma

Ian H. Gabriel, Ruhena Sergeant, Richard Szydlo, Jane F. Apperley, Hugues deLavallade, Abdullah Alsuliman, Ahmad Khoder, David Marin, Edward Kanfer, Nichola Cooper, John Davis, Donald MacDonald, Marco Bua, Letizia Foroni, Chrissy Giles, Dragana Milojkovic, Amin Rahemtulla, Katayoun Rezvani

Blood (2010) 116 (12): 2033–2039.

https://doi.org/10.1182/blood-2010-03-273706

Published: 2010

Journal Articles

Ethnic Disparity in Access to Stem Cell Transplantation for Multiple Myeloma.

Holger W Auner, Hilda Owiti, Chrissy Giles, Jiri Pavlu, Donald MacDonald, Edward Kanfer, Jane F Apperley, Amin Rahemtulla

Blood (2009) 114 (22): 1781.

https://doi.org/10.1182/blood.V114.22.1781.1781

Published: 2009

Journal Articles

Second Autologous Stem Cell Transplantation Is Effective Salvage Therapy for Relapsed Multiple Myeloma.

Aristeidis Chaidos, MD, PhD, Chrissy Giles, B.A.(Hons), Holger W Auner, Marco Bua, Jiri Pavlu, Ellena Smith, Edward Kanfer, MD, Donald MacDonald, Jane F. Apperley, MBChB, FRCP, FRCPath, Amin Rahemtulla, MBBS, PhD, FRCP

Blood (2009) 114 (22): 1229.

https://doi.org/10.1182/blood.V114.22.1229.1229

Published: 2009

Journal Articles

Efficacy, Complication Rates, and Cost Effectiveness of Chemotherapy Plus Granulocyte Colony Stimulating Factor Conditioned Mobilisation of Peripheral Blood Haematopoietic Stem Cells in Over 150 Patients with Haematological Malignancies

Ian H Gabriel, Juliet Sharon, Eduardo Olavarria, MD, Amin Rahemtulla, Edward Kanfer, David Marin, Dragana Milojkovic, Katayoun Rezvani, MD, PhD, Donald MacDonald, Richard M. Szydlo

Blood (2008) 112 (11): 2378.

https://doi.org/10.1182/blood.V112.11.2378.2378

Published: 2008

Journal Articles

Long-Term Outcome after LACE (Lomustine, Ara-C, Cyclophosphamide, Etoposide) Conditioned Autologous Stem Cell Transplantation for Relapsed or Refractory Hodgkin’s Lymphoma: A Single Centre Experience.

Jolanta B. Perz, MD, Chrissy M. Giles, Donald MacDonald, MD, Jane F. Apperley, MD, Edward J. Kanfer, MD

Blood (2005) 106 (11): 5502.

https://doi.org/10.1182/blood.V106.11.5502.5502

Published: 2005

NARROW

MRD4 Eradication at 6 Months and Early Clearance of MRD with Combination of Ibrutinib Plus Venetoclax Results in Sustained Clinical and MRD Responses: Exploratory Analysis of the Blood Cancer UK TAP Clarity Study

Ibrutinib and Obinutuzumab in CLL: MRD Responses Sustained for Several Years with Deepest MRD Depletion in Patients with >1 Year Prior Ibrutinib Exposure

Continued Long Term Responses to Ibrutinib + Venetoclax Treatment for Relapsed/Refractory CLL in the Blood Cancer UK TAP Clarity Trial

Ibrutinib and Obinutuzumab in CLL: Improved MRD Response Rates with Substantially Enhanced MRD Depletion for Patients with >1 Year Prior Ibrutinib Exposure

Ibrutinib Plus Venetoclax in Relapsed/Refractory CLL: Results of the Bloodwise TAP Clarity Study

Initial Results of Ibrutinib Plus Venetoclax in Relapsed, Refractory CLL (Bloodwise TAP CLARITY Study): High Rates of Overall Response, Complete Remission and MRD Eradication after 6 Months of Combination Therapy

The Bloodwise TAP Calibre Feasibility Study to Assess the Mechanism of Action of Idelalisib in B-Cell Receptor Pathway (BCR) Inhibition in Chronic Lymphocytic Leukaemia (CLL)

Preconditioning Neutropenia Is a Key Prognostic Factor in Allogeneic Hematopoietic Cell Transplantation for High Risk Acute Myeloid Leukemia

Updated Analysis of Overall Survival in Randomized Phase III Study of Idelalisib in Combination with Bendamustine and Rituximab in Patients with Relapsed/Refractory CLL

The Intensive Care Trial for Critically Ill Onco-Haematologic Patients: The Need for Response Criteria at 5 Days of Full Treatment to Separate Good Risk Patients and Avoid Futile Intensive Care Interventions

Addition of Obinutuzumab to Ibrutinib Enhances Depletion of CLL Cells in the Peripheral Blood and Bone Marrow after 1 Month of Combination Therapy: Initial Results from the Bloodwise TAP Iciclle Extension Study

Impact of Nutrition on Non-Relapse Mortality and Acute Graft Versus Host Disease during Allogeneic Hematopoietic Cell Transplantation for Hematologic Malignancies

Third Autologous Stem Cell Transplantation for Relapsed Multiple Myeloma

Tandem Autologous Stem Cell Transplantation in Chemorefractory Multiple Myeloma

The Majority of Patients Receiving Donor Lymphocyte Infusions for Relapsed Chronic Myeloid Leukemia Remain PCR Positive Despite Maintaining Long-Term Remission,

Interaction between KIR3DS1 and HLA-Bw4 predicts for progression-free survival after autologous stem cell transplantation in patients with multiple myeloma

Ethnic Disparity in Access to Stem Cell Transplantation for Multiple Myeloma.

Second Autologous Stem Cell Transplantation Is Effective Salvage Therapy for Relapsed Multiple Myeloma.

Efficacy, Complication Rates, and Cost Effectiveness of Chemotherapy Plus Granulocyte Colony Stimulating Factor Conditioned Mobilisation of Peripheral Blood Haematopoietic Stem Cells in Over 150 Patients with Haematological Malignancies

Long-Term Outcome after LACE (Lomustine, Ara-C, Cyclophosphamide, Etoposide) Conditioned Autologous Stem Cell Transplantation for Relapsed or Refractory Hodgkin’s Lymphoma: A Single Centre Experience.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only